The aim of this study is to compare the effectiveness of low-level laser irradiation to traditional topical fluoride treatment for treatment choices of dentinal hypersensitivity following scaling and root planing. The experimental group (15 patients) was treated with low-energy-level diode laser at each site of dentinal hypersensitivity following scaling and root planning. The control group (15 patients) received topical fluoride treatment (protective varnish for desensitization). All the patients were treated at baseline visit, and then at day 2 and 4 after the initial treatment; the pain was subjectively assessed by the patients as strong, medium, medium low, low, or no pain. Total absence of the dental hypersensitivity was reported in 26.66% of the examined group even after the second visit, compared to the control group where complete resolution of the hypersensitivity was not present after the second visit in any of the treated cases. Complete absence of pain was achieved in 86.6% of patients treated with laser and only in 26.6% in the fluoride treated group, after the third visit. Based on our findings, we conclude that low-energy biostimulative laser treatment can be successfully used for treatment of dental hypersensitivity following scaling and root planing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10103-009-0685-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Penn Neurodegeneration Genomics Center, Dept of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: Recent Alzheimer's disease (AD) genome-wide association studies () have identified >75 risk loci, with >98% of genome-wide significant variants residing in non-coding genomic regions, making it more difficult to infer their functional contexts. In this study, we aim to jointly 1) fine-map causal loci/variants, and 2) identify affected cell types and functional elements by interrogating large-scale collections of thousands of heterogenous, cell type-specific functional genomic (FG) datasets.
Method: We analyzed the full genome-wide summary statistics (n = 21,101,114 variants) from the recent AD GWAS (Bellenguez et al, 2022) (Ncases = 111,326, Ncontrols = 677,663).
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia.
Background: Observational studies have suggested a co-occurring relationship between Alzheimer's disease (AD) and asthma. However, the aetiology and biological mechanisms underlying AD and its potential association with asthma, an autoimmune condition, remain unclear.
Method: We examine the genetic relationship between AD and asthma by analysing large-scale genome-wide association study (GWAS) summary data from international research consortia and groups.
The effectiveness of telemedicine methods in the follow-up of asthma in the COVID-19 pandemic process.
Tuberk Toraks
December 2024
Department of Chest Diseases, Manisa Celal Bayar University Faculty of Medicine, Manisa, Türkiye.
Introduction: Telemedicine is a health service that provides diagnosis, treatment evaluation, preventive medicine by using information and communication technologies between distant locations and aims to improve the health of the individuals and society. Social restrictions were applied during the pandemic process caused by coronavirus disease-2019 due to the virus called severe acute respiratory syndrome coronavirus-2 which emerged in late 2019. Through remote communication and information technologies in the followup of asthma patients, there is a need for studies on the effectiveness of using telemedicine methods was seen.
View Article and Find Full Text PDFIdiopathic non-mast cell angioedema: Treatment insights from global experts.
Allergy Asthma Proc
January 2025
From the Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California and.
Idiopathic non-mast cell angioedema (INMA) is a rare disease typified by recurrent attacks of cutaneous and subcutaneous swelling. Every attack carries the potential for severe morbidity and, in the case of laryngeal involvement, mortality. Whereas therapies approved for hereditary angioedema (HAE) have been used in the care of patients with INMA, little is known with regard to their efficacy for the treatment of this disease.
View Article and Find Full Text PDFReal-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan.
Allergy Asthma Proc
January 2025
Department of Pharmacovigilance, Pharmacovigilance and Quality Assurance Group, Torii Pharmaceutical Co., Ltd., Tokyo, Japan.
Standardized quality (SQ) house-dust mite (HDM) sublingual immunotherapy tablets (10,000 Japanese allergy units [JAU], equivalent to 6 SQ-HDM in Europe and the United States) are licensed for the treatment of HDM-induced allergic rhinitis (AR) without age restriction, based on 52-week administration clinical trials. There are no large-scale data on the administration of 10,000 JAU for > 1 year in actual clinical practice. To examine the safety and effectiveness of 10,000 JAU during use for up to 3 years at real-world clinical sites in Japan.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!